CTLA4 and melanoma: Monoclonal antibodies against immune checkpoint receptors, such as CTLA-4, PD-1, and PD-L1, have demonstrated significant results in the treatment of multiple advanced cancers, including melanoma, NSCLC, head and neck, and bladder cancers [26].